Latigo Biotherapeutics completed an upsized IPO in August 2026 that generated $397.4 million in gross proceeds. The proceeds, together with existing cash, are projected to fund current operating plans into 2029, while the company advances onzotrigine, LTG-321 and LTG-418 development programs.

Key Highlights

  • Latigo Biotherapeutics raised gross proceeds of $397.4 million in an upsized initial public offering completed in August 2026.
  • Cash and cash equivalents and restricted cash were $55.197 million as of June 30, 2026.
  • Latigo expects its current cash and cash equivalents, including net IPO proceeds, to fund current operating plans into 2029.

Latigo Biotherapeutics, Inc. (NASDAQ: LTGO) completed an upsized initial public offering in August 2026, raising gross proceeds of $397.4 million. Existing cash and the IPO proceeds are projected to fund current operating plans into 2029. The latest Business update covers onzotrigine, LTG-321 and LTG-418. On September 3, 2026, Latigo said it remained focused on executing development plans for its investigational pain medicines.

Second-Quarter Financial Results

The Balance Sheet showed cash and cash equivalents and restricted cash of $55.197 million at June 30, compared with $69.629 million at Dec 31, 2025. Research and Development expenses reached $21.2 million for the three months ended June 30, 2026, compared with $22.9 million for the same period in 2025. General and administrative expenses were $4.6 million, up from $2.8 million. Net loss was $25.8 million for both three-month periods. Non-cash stock-based compensation expenses were $2.1 million in 2026 and $1.7 million in 2025. Total Assets were $64.760 million at June 30, compared with $75.516 million at Dec 31, 2025.

Onzotrigine Moves Toward Phase 3

Topline results from both onzotrigine Phase 3 trials are expected in the second half of 2027.

Pipeline And Leadership Expansion

The Denmark-based study is evaluating once-daily LTG-321, with enrollment underway, and topline results are expected in the second half of 2027. Latigo completed 14-day non-GLP toxicology studies for LTG-418 in rats and non-human primates, with suitable tolerability demonstrated. The next-generation Nav1.8 inhibitor is being developed for potential acute and chronic pain treatment, while its low-dose design may support formulations and administration routes beyond oral and intravenous delivery.